Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Banner image

Press Release

Fish & Richardson Named 2019 ITC Firm of the Year and Specialty IP Firm of the Year in U.S. by Managing Intellectual Property

April 5, 2019

Press Release

Fish & Richardson Named 2019 ITC Firm of the Year and Specialty IP Firm of the Year in U.S. by Managing Intellectual Property

April 5, 2019

Back to News Listing

Fish & Richardson has been named the 2019 U.S. Firm of the Year in the International Trade Commission (ITC) and Specialty IP categories by Managing Intellectual Property (MIP) magazine. The firm was also named the regional Patent Prosecution (Northeast) Firm of the Year. Fish earned its Firm of the Year awards for having a remarkable year across every venue – garnering more high-profile IP wins in district court, at the ITC, at the Court of Appeals for the Federal Circuit, and at the Patent Trial and Appeal Board (PTAB) than any other firm.

Fish was the most active firm at the ITC in 2018, where it was involved in nearly 17% of all new patent investigations, and secured numerous victories for clients including Macronix International, Aspen Aerogels, Inc., Momentive UV Coatings, and The Chamberlain Group, among others. For Macronix, a leading integrated device manufacturer in the non-volatile memory market, Fish obtained a rare reversal of an administrative law judge’s initial determination of no violation and secured an exclusion order for Macronix against Toshiba Corp. and its subsidiaries. The ITC case made new law regarding the domestic industry requirement.

In district court and at the Federal Circuit, Fish won two blockbuster cases for client Gilead Sciences, Inc., involving the company’s Sovaldi® and Harvoni® drugs, which cure hepatitis C. In Idenix Pharmaceuticals LLC et al. v. Gilead Sciences, Inc., Fish obtained a reversal of a $2.5 billion willful infringement jury verdict against Gilead after proving that Idenix’s patent was invalid due to lack of enablement. In Gilead Sciences, Inc. v. Merck & Co. Inc. et al., Fish won a unanimous Federal Circuit opinion that affirmed its post-trial vacatur of a $200 million jury verdict against Gilead after proving Merck’s unclean hands. The Federal Circuit also affirmed an award of $14 million in attorneys’ fees to Gilead, and the U.S. Supreme Court declined to grant certiorari.

Fish was also the most active firm at the PTAB in 2018, representing petitioners and patent owners in 207 proceedings – 40 more cases than its nearest competitor. Fish has been the most active firm at the PTAB for the past three consecutive years, and recently became the first firm to mark 1,000 appearances in this specialized forum. Major PTAB victories include thwarting 10 inter partes review (IPR) petitions filed against Gilead, persuading the PTAB to deny all 10 petitions.